Shanxi Zhendong Pharmaceutical Co., Ltd. (SHE: 300158) has entered a strategic partnership with Ferring Pharmaceuticals Ltd., the Switzerland-based specialty pharma company, securing exclusive promotion rights to sodium picosulfate in Mainland China. The bowel cleansing agent partnership expands Zhendong’s gastroenterology portfolio while leveraging Ferring’s established product brand in the growing colorectal screening preparation market.
Effective, predictable bowel cleansing for endoscopic procedures
Indication
Bowel preparation prior to colonoscopy, surgery, or radiological examination
Core enabler of China’s expanding colorectal cancer screening programs
Formulation
Oral solution/tablets
Patient-friendly vs. large-volume PEG solutions
Ferring Heritage
Established global brand (Picolax, Dulcolax Pico)
Immediate physician recognition and prescribing confidence
Market Context & Strategic Rationale
Factor
Market Implication
China Colorectal Screening Expansion
National cancer screening programs targeting >100 million high-risk individuals by 2030; bowel preparation agents essential infrastructure
Zhendong Gastroenterology Focus
Listed company building digestive disease franchise; sodium picosulfate complements existing PPI and GI motility portfolio
Ferring China Strategy
Partnership model leverages local promotion expertise while retaining manufacturing and regulatory control; capital-efficient market access
Competitive Landscape
PEG-electrolyte solutions (dominant but poorly tolerated) and sodium phosphate (safety concerns) create opening for improved tolerability profile of picosulfate
Commercial Outlook
Priority
Execution Plan
Hospital Formulary Access
Target tier-1/2 city endoscopy centers and colorectal surgery departments
Screening Program Integration
Position as preferred bowel prep for government-funded CRC screening initiatives
Physician Education
Differentiate vs. PEG volumes via tolerability and compliance messaging
Retail Pharmacy Expansion
Over-the-counter and prescription channel development for outpatient procedures
Forward‑Looking Statements This brief contains forward‑looking statements regarding sodium picosulfate commercial performance in China, Zhendong Pharmaceutical’s gastroenterology market share growth, and Ferring Pharmaceuticals’ partnership expansion strategy. Actual results may differ due to competitive pricing from generic PEG solutions, hospital procurement policy changes, and colorectal screening program funding variability.-Fineline Info & Tech
By Fineline Cube 